RhumbLine Advisers
VTYX

RhumbLine Advisers’s Ventyx Biosciences VTYX Stock Holding History

RhumbLine Advisers’s Portfolio VTYX Stock Details VTYX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-85,928
Closed -$98.8K – 4271
2025
Q1 		$98.8K Sell
85,928
-46,897
-35% -$80.5K ﹤0.01% 3399
2024
Q4 		$291K Buy
132,825
+40,813
+44% +$92.5K ﹤0.01% 3005
2024
Q3 		$201K Buy
92,012
+1,681
+2% +$3.87K ﹤0.01% 3238
2024
Q2 		$209K Buy
90,331
+24,885
+38% +$103K ﹤0.01% 3203
2024
Q1 		$360K Sell
65,446
-12,036
-16% -$55K ﹤0.01% 2870
2023
Q4 		$191K Buy
77,482
+12,853
+20% +$122K ﹤0.01% 3208
2023
Q3 		$2.24M Buy
64,629
+786
+1% +$27.2K ﹤0.01% 1797
2023
Q2 		$2.09M Buy
63,843
+30,952
+94% +$1.07M ﹤0.01% 1880
2023
Q1 		$1.1M Buy
32,891
+2,471
+8% +$96.1K ﹤0.01% 2077
2022
Q4 		$997K Buy
30,420
+2,464
+9% +$73K ﹤0.01% 2129
2022
Q3 		$976K Buy
27,956
+2,519
+10% +$55.8K ﹤0.01% 2144
2022
Q2 		$311K Buy
+25,437
New +$380K ﹤0.01% 2735

Other funds holding VTYX

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

RhumbLine Advisers's VTYX Position: Q2 2025 in Review

RhumbLine Advisers sold out of Ventyx Biosciences (VTYX) in Q2 2025, closing a stake of 85,928 shares — an estimated $98.8K sold.

RhumbLine Advisers first reported a position in VTYX in Q2 2022 and held it in 12 quarters. The position peaked at $2.24M in Q3 2023. 114 funds tracked by Wall St. Rank hold VTYX as of Q2 2025.

  • RhumbLine Advisers reported no remaining Ventyx Biosciences position as of Q2 2025 after selling out during the quarter.
  • RhumbLine Advisers sold 85,928 Ventyx Biosciences shares in Q2 2025, an estimated $98.8K.
  • RhumbLine Advisers first reported a position in Ventyx Biosciences in Q2 2022 and held it in 12 quarters.
  • RhumbLine Advisers's Ventyx Biosciences position peaked at $2.24M in Q3 2023.
  • 114 funds tracked by Wall St. Rank held Ventyx Biosciences as of Q2 2025.

Based on RhumbLine Advisers's 13F filing for Q2 2025, filed 12 Aug 2025.